Acton Pharmaceuticals, Inc. Submits NDA Supplement to FDA for AEROSPAN(R) (flunisolide HFA, 80 mcg) Inhalation Aerosol
MARLBOROUGH, Mass.--(BUSINESS WIRE)--Acton Pharmaceuticals, Inc. today announced that it has submitted to the U.S. Food and Drug Administration (FDA), a Manufacturing Supplement to the previously approved AEROSPAN Inhalation Aerosol NDA. Acton also announced that it has initiated commercial planning and market preparation activities for a product launch into the U.S. market targeted for mid-2011.